ABVC BioPharma enters its May 22 earnings release with short sellers pulling back sharply — the clearest positioning signal ahead of the print.
Short interest has fallen nearly 38% over the past month to 1.2% of the free float. That is a low absolute level, and the direction reinforces it: bears have been covering rather than pressing. Borrow conditions offer no extra ammunition — the cost to borrow is running at roughly 4.5% and has eased around 9% on the week, while availability sits at a comfortable 230%, meaning shares to borrow are plentiful relative to the existing short base. The ORTEX short score of 48 is unexceptional, sitting close to the midpoint of its 0-100 scale.
Options positioning offers a mild counterpoint. The put/call ratio ticked up to 0.50 on Monday, above its 20-day average of 0.38, though the z-score of 0.24 is well within normal range. The recent history shows a short-lived spike into heavy put territory in late April — PCR touched 2.16 on April 20 — which has since fully unwound. That episode looks more like a brief hedge than a sustained directional bet. On price, the stock has given back 20% over the past month to close at $1.09, but clawed back nearly 3% on the week, a modest stabilisation at micro-cap levels.
Analyst and fundamental data are not actionable here. The only available analyst action is a Maxim Group downgrade from 2022 — data too stale to carry weight. Fundamental financials are unavailable for a company of this stage and size, which is typical for pre-revenue clinical-stage biotechs. What is visible is the earnings reaction history: across three recent events, ABVC fell between 2% and 7% on the day of each report, with the five-day window mixed — one modest recovery and one sustained 11% decline.
Closest correlated peers had a rough week. CMMB dropped 6%, MGX fell 7%, and PRTA lost 9% over seven days, suggesting a broadly weak tape for small development-stage names. ABVC, with its 3% weekly gain, has been a relative outperformer against that group — a reversal of the pattern observed in prior periods.
The May 22 print will test whether the covering of short positions reflects genuine improvement in the company's clinical or operational narrative, or simply a low-conviction repositioning ahead of a catalyst that has historically moved the stock lower.
See the live data behind this article on ORTEX.
Open ABVC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
